Swiss Cancer Institute Clinical Trials
Sponsors / Swiss Cancer Institute
The ClinicalTrials.gov registry records 122 trials led by Swiss Cancer Institute. 7 trials are actively recruiting participants, 6 remain active without open enrollment, and 82 have concluded. 24 of these trials ended early via termination or withdrawal. The most common reasons cited for termination include funding constraints, efficacy or futility findings. The cumulative planned enrollment figure across all listed trials is 12,271 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.
122
Total Trials
7
Recruiting
6
Other Active
82
Completed
24
Terminated / Withdrawn
12,271
Total Enrollment
Termination reasons: Funding38% · Other33% · Efficacy13% · Recruitment8% · Business4% · Safety4%
Recent Terminations
- Chronic Lymphocytic Leukemia"The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup."
- Metastatic Castration-resistant Prostate Cancer"SAKK decided to premature terminate this trial as additional follow-up visits do not further contribute to the efficacy data. This decision does not adversely impact the patients."
- Advanced Solid Tumors"The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part."
- Non-Hodgkin Lymphoma"Insufficient Funding"
- Prostate Cancer"Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to one year after last RT fraction of the last patient"
- Soft Tissue Sarcoma"As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on this date in accordance with SAKK/CI."
- Prostate Cancer"Due to lack of funding."
- Squamous-cell Non-small Cell Lung Cancer"Due to financial restructure of SAKK"
- Breast Cancer"Feasibility (low patient accrual and financial reasons)"
- Refractory Multiple Myeloma"Feasibility (low patient accrual and financial reasons)"
Active Trials (6 total)
- NCT07020065
- Bladder Cancer PHASE2NCT04630730
- Bone Metastases PHASE3NCT02051218
- NCT04604067
- Breast Cancer PHASE2NCT06452394
- Sarcoma,Soft Tissue PHASE2NCT06835049
- NCT06090162
- Lung Cancer PHASE2NCT04472949
- NSCLC Stage IIIB PHASE2NCT03620669
- NCT06401980
- NSCLC PHASE2NCT04245514
- NCT06358573
- NCT06114108